Redirecting to https://news.bms.com/news/corporate-financial/2021/U.S.-Food-and-Drug-Administration-Approves-OPDIVO-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-as-First-line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspx...

Click here if your browser doesn't automatically take you to this page.